Vertex Grapples With Bearish Chart As Death Cross Emerges

Benzinga01:23

If You Invested $1000 In This Stock 20 Years Ago, You Would Have This Much Today

BenzingaJan 7 23:45

Vertex, Orna Therapeutics Collaborate on Gene Editing Therapies for Sickle Cell Disease, Beta Thalassemia

MT NewswiresJan 7 23:43

RBC Lifts Price Target on Vertex Pharmaceuticals to $401 From $400, Keeps Sector Perform Rating

MT NewswiresJan 7 20:32 · Ratings

Orna Therapeutics Enters Three-year Strategic Research Collaboration With Vertex Pharmaceuticals; Orna To Receive $65M Upfront Payment And Is Eligible To Receive Up To $635M Milestones

BenzingaJan 7 20:03

Express News | Vertex Pharmaceuticals Inc - Orna to Receive $65 Million Upfront, Eligible for up to $635 Million

BreakingsJan 7 20:00